The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Short Bowel Syndrome Market Research Report 2025
Synopsis
Short bowel syndrome (SBS) is an intestinal disorder associated with malabsorption due to the lack of functional intestine. SBS can be congenital or an acquired condition which can be observed in patients in whom nearly half of the small intestine has been removed due to underlying disease condition.
The global Short Bowel Syndrome market was valued at US$ 444.2 million in 2023 and is anticipated to reach US$ 1362.1 million by 2030, witnessing a CAGR of 17.2% during the forecast period 2024-2030.
The medications prescribed for the treatment of SBS include teduglutide and growth hormones (aid in intestinal absorption), proton pump inhibitors (used to treat gastric acid secretions), and anti-diarrheal (to treat the primary symptom of SBS, i.e., diarrhea). As the patients with SBS have lost major part of the intestine, retaining nutrients in such patients through oral nutrition becomes difficult. Hence parenteral nutrition is the preferred mode of treatment in these patients.
This report aims to provide a comprehensive presentation of the global market for Short Bowel Syndrome, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Short Bowel Syndrome.
Report Scope
The Short Bowel Syndrome market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Short Bowel Syndrome market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Short Bowel Syndrome companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Takeda
Merck
Emmaus Life Sciences
Nutrinia
GlyPharma Therapeutics
OxThera
Ardelyx
Sancilio & Company
Naia Pharmaceuticals
Zealand Pharma
Segment by Type
GLP-2
Growth Hormone
Glutamine
Others
Segment by Application
Hospitals
Clinics
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Short Bowel Syndrome companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Short bowel syndrome (SBS) is an intestinal disorder associated with malabsorption due to the lack of functional intestine. SBS can be congenital or an acquired condition which can be observed in patients in whom nearly half of the small intestine has been removed due to underlying disease condition.
The global Short Bowel Syndrome market was valued at US$ 444.2 million in 2023 and is anticipated to reach US$ 1362.1 million by 2030, witnessing a CAGR of 17.2% during the forecast period 2024-2030.
The medications prescribed for the treatment of SBS include teduglutide and growth hormones (aid in intestinal absorption), proton pump inhibitors (used to treat gastric acid secretions), and anti-diarrheal (to treat the primary symptom of SBS, i.e., diarrhea). As the patients with SBS have lost major part of the intestine, retaining nutrients in such patients through oral nutrition becomes difficult. Hence parenteral nutrition is the preferred mode of treatment in these patients.
This report aims to provide a comprehensive presentation of the global market for Short Bowel Syndrome, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Short Bowel Syndrome.
Report Scope
The Short Bowel Syndrome market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Short Bowel Syndrome market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Short Bowel Syndrome companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Takeda
Merck
Emmaus Life Sciences
Nutrinia
GlyPharma Therapeutics
OxThera
Ardelyx
Sancilio & Company
Naia Pharmaceuticals
Zealand Pharma
Segment by Type
GLP-2
Growth Hormone
Glutamine
Others
Segment by Application
Hospitals
Clinics
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Short Bowel Syndrome companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Short Bowel Syndrome Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 GLP-2
1.2.3 Growth Hormone
1.2.4 Glutamine
1.2.5 Others
1.3 Market by Application
1.3.1 Global Short Bowel Syndrome Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Clinics
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Short Bowel Syndrome Market Perspective (2019-2030)
2.2 Short Bowel Syndrome Growth Trends by Region
2.2.1 Global Short Bowel Syndrome Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Short Bowel Syndrome Historic Market Size by Region (2019-2024)
2.2.3 Short Bowel Syndrome Forecasted Market Size by Region (2025-2030)
2.3 Short Bowel Syndrome Market Dynamics
2.3.1 Short Bowel Syndrome Industry Trends
2.3.2 Short Bowel Syndrome Market Drivers
2.3.3 Short Bowel Syndrome Market Challenges
2.3.4 Short Bowel Syndrome Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Short Bowel Syndrome Players by Revenue
3.1.1 Global Top Short Bowel Syndrome Players by Revenue (2019-2024)
3.1.2 Global Short Bowel Syndrome Revenue Market Share by Players (2019-2024)
3.2 Global Short Bowel Syndrome Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Short Bowel Syndrome Revenue
3.4 Global Short Bowel Syndrome Market Concentration Ratio
3.4.1 Global Short Bowel Syndrome Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Short Bowel Syndrome Revenue in 2023
3.5 Short Bowel Syndrome Key Players Head office and Area Served
3.6 Key Players Short Bowel Syndrome Product Solution and Service
3.7 Date of Enter into Short Bowel Syndrome Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Short Bowel Syndrome Breakdown Data by Type
4.1 Global Short Bowel Syndrome Historic Market Size by Type (2019-2024)
4.2 Global Short Bowel Syndrome Forecasted Market Size by Type (2025-2030)
5 Short Bowel Syndrome Breakdown Data by Application
5.1 Global Short Bowel Syndrome Historic Market Size by Application (2019-2024)
5.2 Global Short Bowel Syndrome Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Short Bowel Syndrome Market Size (2019-2030)
6.2 North America Short Bowel Syndrome Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Short Bowel Syndrome Market Size by Country (2019-2024)
6.4 North America Short Bowel Syndrome Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Short Bowel Syndrome Market Size (2019-2030)
7.2 Europe Short Bowel Syndrome Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Short Bowel Syndrome Market Size by Country (2019-2024)
7.4 Europe Short Bowel Syndrome Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Short Bowel Syndrome Market Size (2019-2030)
8.2 Asia-Pacific Short Bowel Syndrome Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Short Bowel Syndrome Market Size by Region (2019-2024)
8.4 Asia-Pacific Short Bowel Syndrome Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Short Bowel Syndrome Market Size (2019-2030)
9.2 Latin America Short Bowel Syndrome Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Short Bowel Syndrome Market Size by Country (2019-2024)
9.4 Latin America Short Bowel Syndrome Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Short Bowel Syndrome Market Size (2019-2030)
10.2 Middle East & Africa Short Bowel Syndrome Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Short Bowel Syndrome Market Size by Country (2019-2024)
10.4 Middle East & Africa Short Bowel Syndrome Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Takeda
11.1.1 Takeda Company Detail
11.1.2 Takeda Business Overview
11.1.3 Takeda Short Bowel Syndrome Introduction
11.1.4 Takeda Revenue in Short Bowel Syndrome Business (2019-2024)
11.1.5 Takeda Recent Development
11.2 Merck
11.2.1 Merck Company Detail
11.2.2 Merck Business Overview
11.2.3 Merck Short Bowel Syndrome Introduction
11.2.4 Merck Revenue in Short Bowel Syndrome Business (2019-2024)
11.2.5 Merck Recent Development
11.3 Emmaus Life Sciences
11.3.1 Emmaus Life Sciences Company Detail
11.3.2 Emmaus Life Sciences Business Overview
11.3.3 Emmaus Life Sciences Short Bowel Syndrome Introduction
11.3.4 Emmaus Life Sciences Revenue in Short Bowel Syndrome Business (2019-2024)
11.3.5 Emmaus Life Sciences Recent Development
11.4 Nutrinia
11.4.1 Nutrinia Company Detail
11.4.2 Nutrinia Business Overview
11.4.3 Nutrinia Short Bowel Syndrome Introduction
11.4.4 Nutrinia Revenue in Short Bowel Syndrome Business (2019-2024)
11.4.5 Nutrinia Recent Development
11.5 GlyPharma Therapeutics
11.5.1 GlyPharma Therapeutics Company Detail
11.5.2 GlyPharma Therapeutics Business Overview
11.5.3 GlyPharma Therapeutics Short Bowel Syndrome Introduction
11.5.4 GlyPharma Therapeutics Revenue in Short Bowel Syndrome Business (2019-2024)
11.5.5 GlyPharma Therapeutics Recent Development
11.6 OxThera
11.6.1 OxThera Company Detail
11.6.2 OxThera Business Overview
11.6.3 OxThera Short Bowel Syndrome Introduction
11.6.4 OxThera Revenue in Short Bowel Syndrome Business (2019-2024)
11.6.5 OxThera Recent Development
11.7 Ardelyx
11.7.1 Ardelyx Company Detail
11.7.2 Ardelyx Business Overview
11.7.3 Ardelyx Short Bowel Syndrome Introduction
11.7.4 Ardelyx Revenue in Short Bowel Syndrome Business (2019-2024)
11.7.5 Ardelyx Recent Development
11.8 Sancilio & Company
11.8.1 Sancilio & Company Company Detail
11.8.2 Sancilio & Company Business Overview
11.8.3 Sancilio & Company Short Bowel Syndrome Introduction
11.8.4 Sancilio & Company Revenue in Short Bowel Syndrome Business (2019-2024)
11.8.5 Sancilio & Company Recent Development
11.9 Naia Pharmaceuticals
11.9.1 Naia Pharmaceuticals Company Detail
11.9.2 Naia Pharmaceuticals Business Overview
11.9.3 Naia Pharmaceuticals Short Bowel Syndrome Introduction
11.9.4 Naia Pharmaceuticals Revenue in Short Bowel Syndrome Business (2019-2024)
11.9.5 Naia Pharmaceuticals Recent Development
11.10 Zealand Pharma
11.10.1 Zealand Pharma Company Detail
11.10.2 Zealand Pharma Business Overview
11.10.3 Zealand Pharma Short Bowel Syndrome Introduction
11.10.4 Zealand Pharma Revenue in Short Bowel Syndrome Business (2019-2024)
11.10.5 Zealand Pharma Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
